ALTSTATION.IO

Centene Corporation (CNC) Stock Analysis

By Nova Skye | AltStation.io | Updated October 07, 2026

Price
$63.85
Change
-0.69%
Market Cap
$31.54B
Avg Volume
4.6M

Company Overview

Centene Corporation is a healthcare plans provider headquartered in Saint Louis, Missouri, operating in the managed care space since 1984. The company sells health coverage and specialized medical services directly to under-insured families and commercial organizations across the United States. It structures its operations across four segments: Medicaid, Medicare, Commercial, and Other. Through these units, Centene delivers state-backed programs like Medicaid expansion and foster care support, alongside individual marketplace plans, Medicare supplements, prescription drug coverage, and clinical pharmacies. It provides these services through a broad network of primary care doctors, specialty physicians, hospitals, and behavioral health practitioners.

Centene operates as a dominant player in government-sponsored healthcare rather than a traditional corporate insurer. Its core edge comes from scale and specialization in under-insured populations, Medicaid programs, and individual health insurance marketplace products. That concentration cuts both ways, leaving the business directly exposed to state policy shifts and public healthcare funding decisions. Centene also faces steady pressure from competing health plan providers in its Medicare supplement and commercial group lines, where network scale and administrative efficiency drive profitability.

Centene stands as a mature managed care business with four decades of operating history since its 1984 founding. The company balances its primary Medicaid and Medicare divisions with ancillary services in vision, dental, behavioral health, and pharmacy operations under its Other segment. Its primary strategic objective is managing care delivery costs across all four divisions while defending its footprint in Medicaid and commercial exchanges. Overall performance hinges on medical cost discipline and sustaining working relationships across its nationwide network of hospitals and healthcare providers.

Key Financials
Market Cap
$31.54B
Revenue
$180.30B
EBITDA
$4.61B
Gross Margin
11.4%
Profit Margin
-2.8%
Revenue Growth
4.6%
Total Cash
$27.06B
Total Debt
$16.10B
Free Cash Flow
$9.64B


52-Week Price Performance Analysis

Price Statistics
P/E Ratio
N/A
Forward P/E
11.94
Beta
1.13
52-Week High
$69.63
52-Week Low
$31.63
EPS
$-10.66
50-Day Avg
$64.73
200-Day Avg
$52.92
Price/Book
1.40
CNC 52-Week Stock Chart
Technical Analysis
CNC trades at $63.85, placing it 87% of the way from its $31.63 52-week low to its $69.63 high. The stock is 7.21% below that high and 104.27% above the low, confirming a major recovery. Price sits just below the 20-day moving average of $64.25, with the supplied comparison showing a 0.56% difference. Five-day momentum is positive at 3.86%, but 20-day momentum is nearly flat at 0.05%. Near-term support is $60.99, while resistance sits at $69.41.


Recent News and Developments

Wellcare launches its 2027 Medicare lineup

Centene’s Wellcare introduced two nationwide Part D plans covering nearly 10 million members through more than 60,000 pharmacies. Dual-eligible members represent about 40% of Wellcare’s Medicare Advantage membership, and D-SNP products make up nearly half of its 2027 MA offerings. Source: Centene Corporation

Cantor keeps Overweight rating and $75 target

Cantor Fitzgerald reiterated its Overweight rating and $75 price target on Centene. The firm expects Medicare Advantage to reach break-even or better in 2027, driven mainly by footprint reductions rather than pricing changes. Source: Investing.com

Centene cuts nearly one-third of Medicare Advantage plans

Centene will offer 210 Medicare Advantage plans in 2027, down from 303, while standard plans fall from 187 to 110. It is removing standard plans from 344 counties and exiting Hawaii, Oklahoma and Tennessee, a clear margin-first retreat from weaker markets. Source: Becker’s Payer Issues



Market Sentiment and Analyst Recommendations

Bull Case
Centene generates $180.30 billion in revenue and is still growing, with revenue growth of 4.6%. Its $27.06 billion cash position comfortably exceeds its $16.10 billion in total debt. Wellcare’s two nationwide Part D plans cover nearly 10 million members through more than 60,000 pharmacies, giving Centene meaningful Medicare scale. The 2027 strategy is focused on profitability, with Centene cutting weaker Medicare Advantage markets and reducing its plan count from 303 to 210. Cantor Fitzgerald expects Medicare Advantage to reach break-even or better in 2027 and maintains an Overweight rating with a $75 target. The broader analyst consensus is buy across 18 analysts, with a $71.78 average target and targets reaching as high as $85.00. The reason to buy is straightforward: Centene has scale, substantial cash, positive revenue growth and a credible margin-recovery plan.
Bear Case
CNC is already 87% of the way through its 52-week range, so investors are not buying near the bottom. The stock sits only 7.21% below its $69.63 high and faces near-term resistance at $69.41. Twenty-day momentum is just 0.05%, showing that the recent recovery has not produced a strong sustained trend. Centene is cutting Medicare Advantage plans from 303 to 210, while standard plans are falling from 187 to 110. It is also removing standard plans from 344 counties and exiting Hawaii, Oklahoma and Tennessee, which exposes how much of the previous footprint was not working. The P/E ratio is unavailable, making it impossible to judge the stock against a supplied earnings multiple, while the lowest analyst target of $56.00 shows that downside risk remains.
What to Watch
The first technical test is whether CNC can hold the $60.99 near-term support level. On the upside, investors should watch whether the stock can clear $69.41 resistance and then challenge the $69.63 52-week high. CNC closed at $60.99 on October 1, then gained 3.28% on October 2, 2.08% on October 5 and 0.48% on October 6. The October 6 close of $64.61 was 5.9% above the October 1 close, so the next quarter should show whether that rebound has staying power. Operationally, Centene needs to show that reducing Medicare Advantage plans from 303 to 210 can improve margins without damaging the broader business. Investors should also track progress toward Cantor Fitzgerald’s expectation that Medicare Advantage reaches break-even or better in 2027. Revenue growth holding near or above the current 4.6% rate would support the bull case, while a break below $60.99 would weaken it.
Analyst Consensus
BUY

Based on 18 analyst opinions
Low Target
$56.00
Mean Target
$71.78
High Target
$85.00


Earnings and Financial Data

Sector
Healthcare
Industry
Healthcare Plans
Employees
61,100
Earnings & Dividends
Next Earnings
Oct 27, 2026
EPS (Trailing)
$-10.66
Dividend Yield
None
Payout Ratio
0%

Frequently Asked Questions

Is CNC a good stock to buy?
The consensus recommendation is buy based on 18 analysts, and CNC has 4.6% revenue growth. The takeaway is that Wall Street is positive, but the stock is already 87% of the way through its 52-week range.
What is CNC’s price target?
The average analyst target is $71.78, with estimates ranging from $56.00 to $85.00. The takeaway is that analysts see upside potential, but their targets show significant disagreement.
What is CNC’s 52-week high and low?
CNC’s 52-week high is $69.63 and its low is $31.63. The takeaway is that the current $63.85 price sits much closer to the high than the low.
What are CNC’s support and resistance levels?
Near-term support is the 30-day low of $60.99, while resistance is the 30-day high of $69.41. The takeaway is that these are the key technical levels to monitor.
Does CNC pay a dividend?
The supplied data does not include dividend information. The takeaway is that no conclusion about CNC’s dividend can be made from the available data.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated October 07, 2026.